Samuel Bryan

Centinel Spine® to Sponsor Major Worldwide Live Webinar Symposium on Cervical Disc Arthroplasty

Retrieved on: 
Thursday, March 21, 2024
Arthroplasty, PD, Patient, The Company, Doctor of Philosophy, MD, Samuel Bryan, Surgeon, TDR, Spine

This live webinar symposium is open to all spine surgeons worldwide and led by an internationally esteemed group of total disc replacement (TDR) experts.

Key Points: 
  • This live webinar symposium is open to all spine surgeons worldwide and led by an internationally esteemed group of total disc replacement (TDR) experts.
  • A webinar link will allow surgeons worldwide to join for the live presentations, beginning on April 3, 2024 at 8:00am AEDT (April 2, 2024 at 5:00pm EDT U.S.).
  • This symposium is supported by Centinel Spine's global medical education program and is focused on the current state of TDR options for patients with chronic cervical disc disease.
  • Summing up, course co-director Dr. Scott Blumenthal notes, "I strongly encourage any surgeon interested in cervical total disc arthroplasty to attend this symposium.

Coverage Momentum Continues for Lumbar Total Disc Replacement as the Top Commercial Payer in Washington Establishes Positive Coverage

Retrieved on: 
Tuesday, March 12, 2024
Samuel Bryan, Patient, Policy, TDR, The Company, Health insurance

This major positive coverage update continues the trend toward universal coverage for one-level lumbar TDR.

Key Points: 
  • This major positive coverage update continues the trend toward universal coverage for one-level lumbar TDR.
  • Recently, the largest commercial payer in Tennessee, also representing 2.3 million covered lives, established positive coverage for both one- and two-level lumbar TDR procedures.
  • Commercial coverage in the U.S. for two-level lumbar TDR has made tremendous strides over the last two years, now with over 30% commercial coverage.
  • Centinel Spine CEO Steve Murray shared, "It's so encouraging to see these lumbar total disc replacement coverage wins continue.

Coverage Expansion Continues for One- and Two-level Lumbar Total Disc Replacement as the Top Commercial Payer in Tennessee Establishes Positive Coverage for Centinel Spine's prodisc® L

Retrieved on: 
Wednesday, February 21, 2024
TDR, The Company, FDA, Samuel Bryan, Patient, Policy, Acceleration, Pharmaceutical industry

Centinel Spine's prodisc L is the only lumbar TDR system in the U.S. approved for one- and two-level use in the lumbar spine.

Key Points: 
  • Centinel Spine's prodisc L is the only lumbar TDR system in the U.S. approved for one- and two-level use in the lumbar spine.
  • Because prodisc L is the only lumbar TDR device with FDA approval for two-level use, the two-level coverage recommendation only applies to the use of the prodisc L lumbar device.
  • This major positive coverage update continues the trend toward significant coverage for one- and two-level lumbar TDR.
  • In September 2023, the largest commercial payer in Michigan added one- and two-level lumbar TDR coverage, providing 5.7 million covered lives with access to lumbar TDR.

Centinel Spine® PMA Application for First-of-its-Kind 2-Level prodisc® C Vivo and prodisc C SK Match-the-Disc™ Cervical Total Disc Replacement System Filed and Proceeding with Substantive Review

Retrieved on: 
Thursday, October 26, 2023
Anatomy, FDA, Arthroplasty, Investigational device exemption, Food, TDR, Health, PMA, WEST, IDE, Clinical trial, Surgeon, Samuel Bryan, Safety, SK, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Medical device

The clinical trial evaluated the safety and effectiveness of the prodisc C Vivo and prodisc C SK system by comparing it with an approved total disc replacement (TDR) product as a control for 2-level indications.

Key Points: 
  • The clinical trial evaluated the safety and effectiveness of the prodisc C Vivo and prodisc C SK system by comparing it with an approved total disc replacement (TDR) product as a control for 2-level indications.
  • The filing date for the Company's PMA application was September 27, 2023 and the submission is now under substantive review by the FDA.
  • "The prodisc C Vivo and prodisc C SK 2-level cervical disc clinical trial was unique in two ways," said Centinel Spine CEO Steve Murray.
  • The prodisc C Vivo system has been in clinical use internationally since 2009 and is currently one of the most frequently implanted TDR devices in the world.

Centinel Spine Surgical Stadium Event at NASS 2023 to Demonstrate Value of prodisc® Match-the-Disc™ Cervical and Lumbar Total Disc Replacement Systems

Retrieved on: 
Thursday, October 12, 2023
Annual general meeting, North American Spine Society, Faculty, WEST, NASS, TDR, Samuel Bryan, Education, CORE, Surgeon, Patient, Birth control, Medical device

Centinel Spine is the only company to offer cervical and lumbar total disc replacement (TDR) systems that allow matching the disc to the needs of the patient and surgeon.

Key Points: 
  • Centinel Spine is the only company to offer cervical and lumbar total disc replacement (TDR) systems that allow matching the disc to the needs of the patient and surgeon.
  • The prodisc Match-the-Disc™ cervical and lumbar TDR systems will be featured at Centinel Spine's "Surgical Stadium" event to be held on the NASS exhibit floor on October 18 at 2:30pm local time.
  • According to Dr. Hall, "I appreciate that Centinel Spine continues to support total disc arthroplasty education through programs like this NASS Surgical Stadium event.
  • "Continued surgeon education through the NASS Surgical Stadium type of event is critical as the total disc replacement market rapidly accelerates," said Centinel Spine CEO Steve Murray.

Centinel Spine's prodisc® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

Retrieved on: 
Tuesday, October 3, 2023
Surgeon, WEST, Principal investigator, Clinical trial, Intervertebral disc arthroplasty, Spine, Degenerative disc disease, Clinique, PARC, Gold, Publication, MD, Patient, TDR, CORE, IDE, Congress, FDA, Dentistry, Pharmaceutical industry, Medical device, Samuel Bryan

The 250,000 prodisc® Total Disc Replacement (TDR) milestone coincides with the 2023 annual EUROSPINE meeting on October 4-6.

Key Points: 
  • The 250,000 prodisc® Total Disc Replacement (TDR) milestone coincides with the 2023 annual EUROSPINE meeting on October 4-6.
  • Centinel Spine is the only company to offer cervical and lumbar TDR systems that allow matching the disc to the needs of the patient and surgeon.
  • This milestone suggests that total disc replacement has successfully passed the minefields of the 'experimental' phase and proceeded into 'gold standard' territory.
  • In 2006, the next generation prodisc L Lumbar Total Disc Replacement device was approved by the FDA for single-level use.

Silony Medical acquires Centinel Spine's Global Fusion Business

Retrieved on: 
Thursday, September 7, 2023
Spinal fusion, IBF, European Technology Platform on Smart Systems Integration, Ubiquitin A-52 residue ribosomal protein fusion product 1, Samuel Bryan, Sacrum, Health, Instrumented posterior lumbar interbody fusion, 3D printing

FRAUENFELD, Switzerland, Sept. 7, 2023 /PRNewswire/ -- Silony Medical International AG (the company), a growing challenger to "big medtech" in the global spinal fusion market, has signed a definitive agreement to acquire Centinel Spine's Global Fusion Business.  This combines Silony's Verticale® posterior screw & rod fusion System, its Roccia® and Favo® Interbody Fusion (IBF) Systems with the STALIF® Technology Platform to create a first in class occiput to sacrum, posterior, lateral and anterior Spinal Fusion Portfolio for open & minimally invasive spinal fusion cases.

Key Points: 
  • The transaction includes all cervical and lumbar fusion products, including the STALIF® technology platform
    FRAUENFELD, Switzerland, Sept. 7, 2023 /PRNewswire/ -- Silony Medical International AG (the company), a growing challenger to "big medtech" in the global spinal fusion market, has signed a definitive agreement to acquire Centinel Spine's Global Fusion Business.
  • This combines Silony's Verticale® posterior screw & rod fusion System, its Roccia® and Favo® Interbody Fusion (IBF) Systems with the STALIF® Technology Platform to create a first in class occiput to sacrum, posterior, lateral and anterior Spinal Fusion Portfolio for open & minimally invasive spinal fusion cases.
  • "Adding Centinel's Fusion Products to Silony's portfolio significantly strengthens our technological and geographic footprint, without cannibalizing products and sales regions" said Silony CEO Constantin Schoen.
  • Silony is committed to successful long-term relationships, and we look forward to continuing to work with the established STALIF® distributor, surgeon and hospital partners around the world.

Silony Medical acquires Centinel Spine's Global Fusion Business

Retrieved on: 
Thursday, September 7, 2023
Spinal fusion, IBF, European Technology Platform on Smart Systems Integration, Ubiquitin A-52 residue ribosomal protein fusion product 1, Samuel Bryan, Sacrum, Health, Instrumented posterior lumbar interbody fusion, 3D printing

FRAUENFELD, Switzerland, Sept. 7, 2023 /PRNewswire/ -- Silony Medical International AG (the company), a growing challenger to "big medtech" in the global spinal fusion market, has signed a definitive agreement to acquire Centinel Spine's Global Fusion Business.  This combines Silony's Verticale® posterior screw & rod fusion System, its Roccia® and Favo® Interbody Fusion (IBF) Systems with the STALIF® Technology Platform to create a first in class occiput to sacrum, posterior, lateral and anterior Spinal Fusion Portfolio for open & minimally invasive spinal fusion cases.

Key Points: 
  • The transaction includes all cervical and lumbar fusion products, including the STALIF® technology platform
    FRAUENFELD, Switzerland, Sept. 7, 2023 /PRNewswire/ -- Silony Medical International AG (the company), a growing challenger to "big medtech" in the global spinal fusion market, has signed a definitive agreement to acquire Centinel Spine's Global Fusion Business.
  • This combines Silony's Verticale® posterior screw & rod fusion System, its Roccia® and Favo® Interbody Fusion (IBF) Systems with the STALIF® Technology Platform to create a first in class occiput to sacrum, posterior, lateral and anterior Spinal Fusion Portfolio for open & minimally invasive spinal fusion cases.
  • "Adding Centinel's Fusion Products to Silony's portfolio significantly strengthens our technological and geographic footprint, without cannibalizing products and sales regions" said Silony CEO Constantin Schoen.
  • Silony is committed to successful long-term relationships, and we look forward to continuing to work with the established STALIF® distributor, surgeon and hospital partners around the world.

Centinel Spine® Announces Record Worldwide prodisc® Total Disc Replacement Revenue and EBITDA-Positive Second Quarter 2023

Retrieved on: 
Tuesday, August 1, 2023
Surgeon, International, SK, WEST, Disc, Intervertebral disc arthroplasty, Competitive landscape, YOY, Traction, MD, Patient, TDR, Growth, Geography, Video game, Pharmaceutical industry, Samuel Bryan

Second quarter 2023 worldwide prodisc® Total Disc Replacement (TDR) revenue exceeded $17.5 million in sales—a new record—on 64% growth over second quarter 2022 and sequential 24% growth over first quarter 2023, the company's previous best quarter.

Key Points: 
  • Second quarter 2023 worldwide prodisc® Total Disc Replacement (TDR) revenue exceeded $17.5 million in sales—a new record—on 64% growth over second quarter 2022 and sequential 24% growth over first quarter 2023, the company's previous best quarter.
  • Centinel Spine CEO Steve Murray shared, "We are pleased to have had our fifth consecutive record quarter of prodisc TDR revenue, worldwide.
  • Second quarter 2023 revenue for the Company's worldwide prodisc TDR business exceeded $17.5 million (a record for the company), with 64% growth over Q2 2022 and sequential growth of 24% over Q1 2023 (previous record quarter).
  • Nearly 800 procedures were completed with the new system in the second quarter 2023, representing over 50% sequential procedure volume growth versus first quarter 2023.

Top Commercial Payer in Michigan Significantly Expands Patient Access to Centinel Spine's prodisc® L for One- and Two-level Lumbar Total Disc Replacement

Retrieved on: 
Wednesday, July 26, 2023
WEST, Policy, Quality of life, Outline, Publication, Patient, Samuel Bryan, DDD, TDR, Health insurance

The largest commercial payer in Michigan, representing 5.8 million covered lives, has established positive coverage effective September 1 2023 for both one- and two-level lumbar total disc replacement (LTDR) procedures, which includes prodisc®L.

Key Points: 
  • The largest commercial payer in Michigan, representing 5.8 million covered lives, has established positive coverage effective September 1 2023 for both one- and two-level lumbar total disc replacement (LTDR) procedures, which includes prodisc®L.
  • This major positive coverage update continues the trend for one-level lumbar TDR over the last several years, moving the number of covered lives from under 50% in 2017 to now approaching universal coverage for commercial payers.
  • The commercial payer, the largest operating payer in Michigan, previously had no coverage policy for either one- or two-level lumbar TDR.
  • The new positive coverage policy opens access to patients suffering from symptomatic degenerative disc disease (DDD) who can benefit from lumbar TDR using prodisc L for both one- and two-level lumbar TDR.